Hypoimmune, Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive Immune Rejection for the Treatment of Large B Cell Lymphoma Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell TherapyAdam Johnson, Terry J. Fry, Chris Baldeviano et al.|Blood|2023Cited by 4
Development of a Novel, Allogeneic GPRC5D-Directed CAR for Treatment of Multiple Myeloma PatientsJeremy M. Kinder, Terry J. Fry, Chanel Athena Estrada et al.|Blood|2023Cited by 3
BCMA-Targeted, Hypoimmune Allogeneic CAR T Cells Exhibit Potent Anti-Tumor Activity Together with the Ability to Evade Innate and Adaptive Immune Rejection in Pre-Clinical Tumor ModelsJeremy M. Kinder, Aaron E. Foster, Chanel Athena-Estrada et al.|Blood|2022Cited by 1
Abstract 2735: Development of a novel, fully human anti-CD19 chimeric antigen receptor for <i>in vivo</i> delivery via CD8-targeted fusosomeJeremy M. Kinder, Aaron E. Foster, Christie Ciarlo et al.|Cancer Research|2023Cited by 0